Johnson & Johnson's Investigational Drug JNJ-88549968 Injection Receives IND Approval in China for Myeloproliferative Neoplasms

Economic Observer NetworkOn March 31, 2026, the Phase 1 new drug JNJ-88549968 injection, filed by Johnson & Johnson, was approved for clinical trials in China. It is under development for the treatment of myeloproliferative neoplasms, marking the latest progress in its bispecific antibody R&D pipeline.

The above content is based on publicly available information and does not constitute investment advice.